Diligence memo · auto-generated · as of July 2, 2026
Cage Pharmaceuticals, Inc.
Cage Pharmaceuticals, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Cage Pharmaceuticals, Inc. operates in Biotech / Pharma, based in New York.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cage Pharmaceuticals, Inc. has raised $967K in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $480K on 2019-07-10.
Most recent recorded round closed around 2024-05-01.
Valuation (modeled)modeled
Provath models Cage Pharmaceuticals, Inc. at approximately $696K (range $75K–$2.5M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.33× the median modeled value of Pre-Seed Biotech / Pharma companies in 2022–2024 (28 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 38 months.
Last raise 2.2 yr ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
The last round was 3.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 29% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 7% of those peers.
Closest niche peers: Gaingels Oct Bio LLC, Gaingels Alto Pharmacy LLC, Pyros Pharmaceuticals, Inc., Allander Biotechnologies, Inc., CyMon Bio, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.